MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary – MYND Diagnostics Ltd. Oct 7, 2021
NeonMind Strengthens its Specialty Clinics Advisory Board with Appointment of Mood Disorders and Ketamine Expert Dr.… Sep 22, 2021
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression Sep 14, 2021
Mindset Pharma Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocybin Analog through Drug… Sep 14, 2021
MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders Aug 24, 2021
Cybin Strengthens IP Portfolio By Filing Of 16th Patent Application: Psychedelic Investors React Aug 20, 2021
